Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Varese – page 80

2 655 clinical trials in Varese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Varese at a glance
2 655
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 655 trials in Varese

Open in trial search

Metastatic gastric cancer

Recruiting

Study on Dostarlimab Immunotherapy for Patients with Localized Gastric Cancer with Deficient Mismatch Repair or High Microsatellite Instability

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Association Gercor

Pericarditis

Recruiting

Study Comparing Anakinra and Prednisone for Children with Colchicine-Resistant Recurrent Pericarditis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:IRCCS Istituto Giannina Gaslini

Nasal sinus cancer

Recruiting

Study of Pembrolizumab and Chemotherapy for Patients with Locally Advanced Sinonasal Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb

Post-acute COVID-19 syndrome

Recruiting

Study on Anakinra for Patients with Long COVID and Ongoing Respiratory Symptoms

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Non-small cell lung cancer

Recruiting

Study on the Safety and Effectiveness of Zipalertinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Specific EGFR Mutations

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Digoxin
  • Sponsor:Taiho Oncology Inc.

Systemic lupus erythematosus

Recruiting

Study of Anifrolumab for Children and Teens with Moderate to Severe Lupus

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Plasma cell myeloma

Recruiting

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Prophylaxis of nausea and vomiting

Recruiting

Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on the Safety and Tolerability of ODM-212 for Patients with Advanced Solid Tumors

Recruiting
InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Orion Corporation

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Breast cancer metastatic+1

Recruiting

Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Varese

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on blood cancers and lymphomas, including studies of novel therapies for acute myeloid leukemia and chronic myeloid leukemia. Clinical trials are evaluating innovative treatment combinations and maintenance strategies.

  • Follicular Lymphoma Treatment Optimization
  • Leukemia Targeted Therapies
  • B-cell Lymphoma Management

Investigations include maintenance therapies and comparison of shortened versus standard chemotherapy protocols combined with immunotherapy.

02 Thoracic Oncology

Comprehensive studies on non-small cell lung cancer and pleural mesothelioma, exploring innovative combination therapies and targeted treatments for specific genetic mutations.

  • EGFR-TKI Sequencing Studies
  • Immunotherapy Combinations
  • Targeted Molecular Therapies

Research focuses on personalized treatment approaches and novel drug combinations to improve patient outcomes.

03 Cardiovascular Medicine

Advanced research in cardiovascular disease and thrombosis, with trials examining innovative treatments for reducing cardiovascular events and managing blood clots.

  • Lipoprotein Management
  • Deep Vein Thrombosis Treatment
  • Cardiovascular Risk Reduction

Studies aim to evaluate new therapeutic approaches for preventing major cardiovascular events and improving patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.